Bedaquiline plus delamanid for XDR tuberculosis

The combination was initiated in a patient in whom an effective treatment cannot be designed, in the consideration that its potential life-saving benefits outweigh its unknown adverse event risks; in a department in which more than 100 tuberculosis cases a year are admitted to hospital, of which 14...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The Lancet infectious diseases Jg. 16; H. 3; S. 294
Hauptverfasser:	Lachâtre, Marie, Rioux, Christophe, Dû, Damien Le, Fréchet-Jachym, Mathilde, Veziris, Nicolas, Bouvet, Elisabeth, Yazdanpanah, Yazdan
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Elsevier Ltd 01.03.2016 Elsevier Limited
Schlagworte:	Antitubercular Agents - therapeutic use Diarylquinolines - therapeutic use Extensively Drug-Resistant Tuberculosis - drug therapy Extensively Drug-Resistant Tuberculosis - surgery Health Services Accessibility Humans Infectious Disease Infectious diseases Male Mycobacterium Nitroimidazoles - therapeutic use Oxazoles - therapeutic use Tuberculosis
ISSN:	1473-3099, 1474-4457, 1474-4457
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!